Drugs / ITIL-306
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05397093 | Aug 2022 → Oct 2023 | malignant epithelial tumor of ovary, non-small cell lung carcinoma, renal cell carcinoma | Instil Bio | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-11-06 | Instil Bio | Results Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting instilbio.com ↗
Additionally, CoStAR was demonstrated to enhance the secretion of soluble factors from CD4+ T cells to boost the proliferation and survival of companion CD8+ T cells. |
| 2023-06-26 | Instil Bio | Results Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference instilbio.com ↗
The robust activity of NSCLC, ovarian, and renal carcinoma CoStAR-TILs against autologous tumor exceeded that of genetically unmodified melanoma TILs, as measured by secretion of IFNγ. |
| 2022-05-27 | Instil Bio | Regulatory Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment instilbio.com ↗
FDA granted IND clearance for ITIL-306, Instil’s first genetically-engineered CoStAR-TIL therapy for the treatment of NSCLC, RCC, and ovarian cancer |
| 2021-11-15 | Instil Bio | Results Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting instilbio.com ↗
The results demonstrated that CoStAR broadly enhances effector function of T cells including cytolytic activity, cytokine secretion and proliferation of T cells. |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ITIL-306 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05397093 ↗ |
| Modality | Cell therapy | “ITIL-306 is a cell therapy product” NCT05397093 ↗ |